Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

3 Jan 2012 07:00

RNS Number : 8394U
ViaLogy PLC
03 January 2012
 



ViaLogy PLC ("ViaLogy" or "the Company")

 

Business update

 

Pasadena, January 3, 2012. ViaLogy PLC (VIY LSE/AIM), a provider of reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas Exploration and Production companies based on proprietary, patented active signal processing technology, reports substantial progress has been achieved in consolidating relationships with major oil and gas exploration companies on three continents during the last quarter of 2011. In Asia, a contract with a National Oil Company awaits government approval to transfer seismic information before it is signed. In the US, a pilot contract with a supermajor has been completed and acknowledged as positive by the client, and for a large independent exploration company a blind test determined porosity features across a 60 sq km prospect in Texas. In Europe, at the invitation of another supermajor, ViaLogy scientists briefed over 50 company geophysicists around the world on QuantumRD, its powerful computational weak signal processing technology which aids the discovery, characterization, and sizing of hydrocarbon deposits.

In updating the Company's progress to bring the technology to the attention of the O&G giants, CEO Robert W. Dean acknowledges that there have been time frustrations beyond ViaLogy's control; "Unforeseen delays unrelated to our work have affected the consummation of contracts," he said.

In Asia, ViaLogy expects contract awards from two global E&P companies. The first such contract, with a National Oil Company, the contract award process has been dictated by standard procedures and timelines already in place for work performed on government leased fields. Now, however, negotiations have been concluded and contract terms agreed. The final phase involves obtaining approval from the government for the export of seismic data to ViaLogy's US headquarters in Pasadena. In the second case, many similar rules apply both to leaseholder and ViaLogy, but the ViaLogy board believe that the contract process is now on track to award.

In the US, results from ViaLogy's pilot contract for its current supermajor client have been acknowledged as positive and have presented results and conclusions on porosity values that would be unattainable with technology now in use by the client. Their quantitative analysis continues, and should result in further contract work under our already-signed Master Services Agreement.

Another ViaLogy success, this one for a large US-based independent, determined porosity features across a 60 sq km prospect in Texas. In this blind test of the technology porosity values were determined in five Permian formations using seismic data from which other analysis techniques had been unable to extract this information. The client confirms this and is conducting further quantitative evaluation. Accurate predictions of porosity are fundamental in identifying hydrocarbon locations, and a measure of QuantumRD's ability to add breakthrough value in the seismic analysis industry.

Involvement in Europe resulted from an unsolicited approach to ViaLogy by a second supermajor in September. Now detailed technical examination is underway and has been ongoing for over three months. The process has extended to multiple locations, and the supermajor has engaged its most senior technical and scientific staff, as well as its operational management.

"Running this gauntlet of rigorous technical scrutiny takes time and concentration, but is at the heart of client recruitment for us in this 'big tent' part of the industry. It will serve ViaLogy well going forward, and should result in contracted project work," said Mr. Dean.

 

 

For further information:

 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 207 107 8000

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLGDBIBGBGDD
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.